MARAVAI LIFESCIENCES HOLDINGS, INC.
MRVINasdaq
$7.24
↑ +2.1%Jul 17 close · end-of-day
Price
1Y↑ +187.3%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$1.1B
Enterprise Value
$1.1B
P/E
—
P/S
5.2
P/B
5.0
EV/EBITDA
—
PEG
—
FCF Yield
-5.0%
Dividend Yield
—
Revenue (TTM)
$204.7M
Net Income (TTM)
-$104.6M
Free Cash Flow (TTM)
-$52.6M
Gross Margin
—
Operating Margin
-82.2%
Net Margin
-51.1%
ROE
-49.4%
ROIC
-46.4%
Debt / Equity
1.1
Net Cash
-$75.1M
Return 1Y
+188.5%
Company profile
Maravai LifeSciences Holdings, Inc. provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics.
- CEO
- Carl W. Hull
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 610
- Headquarters
- California
- Website
- maravai.com
Management & directors
- Brust BerndChief Executive Officer
- Asarpota RajeshChief Financial Officer
- Oreshack KurtGeneral Counsel
- Dolan ChristineSee Remarks
- Leddy Peter MichaelSee Remarks
Roles derived from SEC Form 4 filings.
Earnings
MRVI Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$65.8M↑ +40.5%
Diluted EPS-$0.02↓ -90.5%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $284.1M | $799.2M | $883.0M | $288.9M | $259.2M | $185.7M |
| Gross profit | — | — | — | $140.2M | $108.3M | $34.0M |
| Operating income | $119.9M | $554.6M | $574.2M | -$31.6M | -$235.6M | -$215.3M |
| Net income | $89.0M | $469.3M | $490.7M | -$138.4M | -$144.8M | -$130.8M |
| Diluted EPS | $2.36 | $1.56 | $1.67 | -$0.90 | -$1.05 | -$0.90 |
| Operating cash flow | $152.2M | $368.6M | $536.0M | $126.2M | $7.5M | -$57.6M |
| Free cash flow | $126.8M | $353.7M | $518.9M | $60.7M | -$22.2M | -$70.7M |
| Gross margin | — | — | — | 48.5% | 41.8% | 18.3% |
| Operating margin | 42.2% | 69.4% | 65.0% | -11.0% | -90.9% | -115.9% |
| Net margin | 31.3% | 58.7% | 55.6% | -47.9% | -55.9% | -70.4% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $69.4M | $69.0M | $56.6M | $46.9M | $47.4M | $41.6M | $49.9M | $65.8M |
| Gross profit | — | $32.2M | — | $7.7M | — | $5.7M | — | $33.7M |
| Operating income | -$13.4M | -$165.6M | -$37.7M | -$49.2M | -$66.3M | -$41.0M | -$58.8M | -$2.2M |
| Net income | -$9.8M | -$97.1M | -$25.9M | -$29.9M | -$39.6M | -$25.6M | -$35.7M | -$3.7M |
| Diluted EPS | -$0.07 | -$0.68 | -$0.21 | -$0.21 | -$0.27 | -$0.18 | -$0.24 | -$0.02 |
| Operating cash flow | $17.4M | $13.1M | -$14.6M | -$9.4M | -$10.3M | -$15.2M | -$22.8M | $8.7M |
| Free cash flow | $7.9M | $4.5M | -$20.5M | -$13.9M | -$13.9M | -$18.1M | -$24.9M | $4.2M |
| Gross margin | — | 46.7% | — | 16.5% | — | 13.6% | — | 51.2% |
| Operating margin | -19.4% | -239.9% | -66.7% | -104.9% | -139.8% | -98.6% | -117.9% | -3.3% |
| Net margin | -14.1% | -140.6% | -45.7% | -63.9% | -83.5% | -61.4% | -71.6% | -5.7% |
Company news
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-08 | Brust Bernd· Chief Executive Officer | Tax withholding | 29,250 | $5.92 | $173,160.00 | filing |
| 2026-06-30 | Asarpota Rajesh· Chief Financial Officer | Tax withholding | 65,584 | $6.39 | $419,081.76 | filing |
| 2026-06-10 | ORESHACK KURT· General Counsel | Sale | 25,000 | $5.10 | $127,500.00 | filing |
| 2026-06-09 | ORESHACK KURT· General Counsel | Sale | 25,000 | $5.06 | $126,500.00 | filing |
| 2026-06-09 | LUCIER GREGORY T | Gift | 46,293 | $0.00 | $0.00 | filing |
| 2026-06-09 | LUCIER GREGORY T | Gift | 46,293 | $0.00 | $0.00 | filing |
| 2026-06-08 | Brust Bernd· Chief Executive Officer | Tax withholding | 351,001 | $5.02 | $1.8M | filing |
| 2026-05-26 | LUCIER GREGORY T | Award | 46,293 | $4.38 | $202,763.34 | filing |
| 2026-05-26 | CUNNINGHAM SEAN LAURENCE | Award | 46,293 | $0.00 | $0.00 | filing |
| 2026-05-26 | LUCIER GREGORY T | Award | 46,293 | $0.00 | $0.00 | filing |
| 2026-05-26 | MARKER LUKE JOSEPH | Award | 46,293 | $0.00 | $0.00 | filing |
| 2026-05-26 | GRAY SUSANNAH | Award | 46,293 | $0.00 | $0.00 | filing |
| 2026-05-26 | MIHAS CONSTANTINE S | Award | 46,293 | $0.00 | $0.00 | filing |
| 2026-05-26 | ECKERT R ANDREW | Award | 46,293 | $0.00 | $0.00 | filing |
| 2026-05-26 | DeFord John A | Award | 46,293 | $0.00 | $0.00 | filing |
| 2026-05-15 | Dolan Christine· See Remarks | Award | 5,006 | $1.79 | $8,960.74 | filing |
| 2026-05-15 | ORESHACK KURT· General Counsel | Award | 776 | $2.84 | $2,203.84 | filing |
| 2026-03-16 | ORESHACK KURT· General Counsel | Tax withholding | 39,976 | $3.08 | $123,126.08 | filing |
| 2026-03-16 | Dolan Christine· See Remarks | Tax withholding | 28,661 | $3.08 | $88,275.88 | filing |
| 2026-01-15 | ORESHACK KURT· General Counsel | Tax withholding | 31,902 | $3.69 | $117,718.38 | filing |
| 2026-01-15 | Dolan Christine· See Remarks | Tax withholding | 28,934 | $3.69 | $106,766.46 | filing |
| 2025-12-08 | LUCIER GREGORY T | Buy | 48,528 | $3.67 | $178,097.76 | filing |
| 2025-12-05 | LUCIER GREGORY T | Buy | 51,472 | $3.70 | $190,446.40 | filing |
| 2025-11-14 | Dolan Christine· See Remarks | Award | 4,300 | $1.79 | $7,697.00 | filing |
| 2025-11-13 | Brust Bernd· Chief Executive Officer | Buy | 216,212 | $3.25 | $702,689.00 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.